ReviewHematology/oncology clinics of North America2011
mTOR inhibitors in advanced renal cell carcinoma.
Review in Hematology/oncology clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies.Biomarker research · 2025Review
- Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions.Journal of cancer immunology · 2025Article
- Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.Cells · 2023Article
- Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma.Journal of clinical medicine · 2023Review
- Review
- Article
- Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.Nature reviews. Urology · 2023Review
- PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma.Cancer research and treatment · 2023Article
- Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.Nature reviews. Urology · 2022Review
- Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.Cancers · 2022Review
- IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma.Frontiers in oncology · 2022Review
- Function and Therapeutic Implications of tRNA Derived Small RNAs.Frontiers in molecular biosciences · 2022Review
- Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study.Clinical imaging · 2021Observational
- Racially Disparate Expression of mTOR/ERK-1/2 Allied Proteins in Cancer.Frontiers in cell and developmental biology · 2021Review
- Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.Frontiers in immunology · 2021Review
- Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.Investigational new drugs · 2020Article
- Autophagy as a Vital Therapy Target for Renal Cell Carcinoma.Frontiers in pharmacology · 2020Review
- ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Better understanding of the molecular biology of renal cell carcinoma (RCC) has led to the development of several targeted anti-cancer agents, several of which have since received approval for treatment of advanced disease. Two of these, the intravenous agent temsirolimus and the oral everolimus, exhibit antitumor effects through inhibition of the mammalian target of rapamycin (mTOR) pathway. This article reviews their mechanisms of action in the context of the current understanding of RCC pathophysiology, the clinical data leading to their approval, class-specific toxicities, potential molecular mechanisms behind treatment resistance and novel treatment approaches for RCC that incorporate mTOR blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.